Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists
作者:Charles J. McIntyre、John A. McCauley、Bohumil Bednar、Rodney A. Bednar、John W. Butcher、David A. Claremon、Michael E. Cunningham、Roger M. Freidinger、Stanley L. Gaul、Carl F. Homnick、Ken S. Koblan、Scott D. Mosser、Joseph J. Romano、Nigel J. Liverton
DOI:10.1016/j.bmcl.2009.07.028
日期:2009.9
A novel series of annulated tricyclic compounds was synthesized and evaluated as NMDA/NR2B antagonists. Structure-activity development was directed towards in vitro optimization of NR2B activity and selectivity over the hERG K+ channel. Preferred compounds were subsequently evaluated for selectivity in an alpha(1)-adrenergic receptor binding counter-screen and a cell-based assay of NR2B activity. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINE NMDA/NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINES DE NMDA/NR2B
申请人:MERCK & CO INC
公开号:WO2003084931A1
公开(公告)日:2003-10-16
Benzo [4,5]cyclohepta[1,2-b]pyridines represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.